150 related articles for article (PubMed ID: 8615021)
1. Inhibition of HIV infection by pseudopeptides blocking viral envelope glycoprotein-mediated membrane fusion and cell death.
Callebaut C; Jacotot E; Guichard G; Krust B; Rey-Cuille M; Cointe D; Benkirane N; Blanco J; Muller S; Briand J; Hovanessian AG
Virology; 1996 Apr; 218(1):181-92. PubMed ID: 8615021
[TBL] [Abstract][Full Text] [Related]
2. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
3. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
[TBL] [Abstract][Full Text] [Related]
4. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
5. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
7. The V3 loop-mimicking pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits HIV infection in primary macrophage cultures.
Seddiki N; Nisole S; Krust B; Callebaut C; Guichard G; Muller S; Briand JP; Hovanessian AG
AIDS Res Hum Retroviruses; 1999 Mar; 15(4):381-90. PubMed ID: 10082122
[TBL] [Abstract][Full Text] [Related]
8. Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein.
Callebaut C; Jacotot E; Krust B; Guichard G; Blanco J; Valenzuela A; Svab J; Muller S; Briand JP; Hovanessian AG
J Biol Chem; 1997 Mar; 272(11):7159-66. PubMed ID: 9054411
[TBL] [Abstract][Full Text] [Related]
9. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.
de Vreese K; Kofler-Mongold V; Leutgeb C; Weber V; Vermeire K; Schacht S; Anné J; de Clercq E; Datema R; Werner G
J Virol; 1996 Feb; 70(2):689-96. PubMed ID: 8551604
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
Debnath AK; Jiang S; Strick N; Lin K; Haberfield P; Neurath AR
J Med Chem; 1994 Apr; 37(8):1099-108. PubMed ID: 8164251
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effects of milk proteins: acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro.
Swart PJ; Kuipers ME; Smit C; Pauwels R; deBéthune MP; de Clercq E; Meijer DK; Huisman JG
AIDS Res Hum Retroviruses; 1996 Jun; 12(9):769-75. PubMed ID: 8738428
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
13. The HB-19 pseudopeptide 5[Kpsi(CH2N)PR]-TASP inhibits attachment of T lymophocyte- and macrophage-tropic HIV to permissive cells.
Nisole S; Krust B; Dam E; Bianco A; Seddiki N; Loaec S; Callebaut C; Guichard G; Muller S; Briand JP; Hovanessian AG
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):237-49. PubMed ID: 10710212
[TBL] [Abstract][Full Text] [Related]
14. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
15. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
16. Single basic amino acid substitutions at position 302 or 320 in the V3 domain of HIV type 1 are not sufficient to alter the antiviral activity of dextran sulfate and heparin.
Okada T; Gurney ME
AIDS Res Hum Retroviruses; 1995 May; 11(5):571-5. PubMed ID: 7576913
[TBL] [Abstract][Full Text] [Related]
17. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.
Yahi N; Fantini J; Mabrouk K; Tamalet C; de Micco P; van Rietschoten J; Rochat H; Sabatier JM
J Virol; 1994 Sep; 68(9):5714-20. PubMed ID: 8057453
[TBL] [Abstract][Full Text] [Related]
18. Minimal sequence requirements for synthetic peptides derived from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) to enhance HIV-1 binding to cells and infection.
Zanotto C; Calderazzo F; Dettin M; Di Bello C; Autiero M; Guardiola J; Chieco-Bianchi L; De Rossi A
Virology; 1995 Feb; 206(2):807-16. PubMed ID: 7856094
[TBL] [Abstract][Full Text] [Related]
19. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
20. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
